# BPC-157 TB-500 FAQ: The Wolverine Blend, Answered and Cited > BPC-157 TB-500 FAQ — 25 direct, cited answers on the Wolverine blend: mechanisms, the combination gap, dosage context, FDA 503A status, WADA, and safety. The 25 most-asked questions about the Wolverine blend — definitions, mechanisms, evidence, dosage context, and access — each answered directly and cited. ## Definitions and the pairing ### What is the Wolverine peptide blend? A research-community name for a two-peptide pairing of BPC-157 (a cytoprotective, angiogenic pentadecapeptide) with TB-500 (the synthetic `Ac-LKKTETQ` actin-binding fragment of Thymosin Beta-4), discussed as a tissue-repair "stack" [5]. It is not a single chemical entity or an approved product, and the name is conflated with the X-Men character. ### What is BPC-157 and TB-500? BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a human gastric-juice protein. TB-500 is a synthetic N-acetylated heptapeptide (`Ac-LKKTETQ`) corresponding to the actin-binding region of Thymosin Beta-4 [5]. The blend pairs the two for their complementary proposed tissue-repair mechanisms. ### What is the BPC-157 and TB-500 blend used for in research? It is studied — as separate constituents, in animal models — for tendon, ligament, muscle, and wound repair and for angiogenesis [1][4]. No controlled study has evaluated the combination itself in humans [6]. ### What is the difference between BPC-157 and TB-500? BPC-157 is a 15-amino-acid gastric-juice-derived peptide acting via VEGFR2/eNOS angiogenesis and growth-hormone-receptor sensitization [2]. TB-500 is a 7-amino-acid actin-binding fragment of Thymosin Beta-4 acting via G-actin sequestration and cell migration [3]. Different sequences, sizes, and proposed mechanisms. ### Why are BPC-157 and TB-500 combined (the Wolverine stack)? The rationale is complementary mechanisms: BPC-157 supplies a local cytoprotective and pro-angiogenic signal (VEGFR2-Akt-eNOS) [2], while TB-500 / Thymosin Beta-4 supplies an actin-sequestration signal driving cell migration [3]. This synergy is a theoretical extrapolation — no controlled combination study has defined a synergistic dose, ratio, or endpoint [6]. ## Mechanisms ### How does TB-500 work (actin / Thymosin Beta-4)? TB-500's `LKKTETQ` motif binds monomeric (G-) actin 1:1 and sequesters it by capping both ends, regulating the actin dynamics that drive cell migration and re-epithelialization. X-ray crystallography of a gelsolin-domain-1-Tβ4 hybrid bound to actin established this structural basis [3]. ### How does BPC-157 work compared to TB-500? BPC-157 acts mainly extracellularly and locally — up-regulating VEGFR2 with downstream Akt-eNOS angiogenic and cytoprotective signaling, and sensitizing tendon fibroblasts to growth hormone [2]. TB-500 acts intracellularly on the cytoskeleton via G-actin sequestration [3]. The pathways are described as complementary but largely non-overlapping. ### Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)? In preclinical models, BPC-157 is pro-angiogenic via VEGFR2 up-regulation and internalization with downstream VEGFR2-Akt-eNOS signaling [2], and Thymosin Beta-4 promotes angiogenesis through endothelial migration [4]. The two are described as parallel routes to improved tissue perfusion. ## Evidence and the combination gap ### Are there human clinical trials on the BPC-157 + TB-500 combination? No. There are no controlled clinical trials of the BPC-157 + TB-500 combination for any indication. Human data exist only for the individual constituents and are thin: three small BPC-157 pilot studies, and "TB-500" human data that are actually for full-length thymosin beta-4, not the 7-mer [6]. ### Is there any study showing BPC-157 and TB-500 work better together (synergy)? No. No peer-reviewed combination study defines a synergy ratio, dose, or endpoint for the two peptides given together. The 2025 HSS Journal systematic review of BPC-157 makes no mention of TB-500 or combination use; "synergy" claims are extrapolations from each peptide's separate mechanism [6]. ### What do doctors and reviews say about the BPC-157 + TB-500 blend? Recent peer-reviewed reviews describe animal-model promise but scarce human safety data, the lowest tiers of evidence (level IV-V), and no controlled combination study, and recommend treating the constituents as investigational and used with caution given regulatory controversy and non-regulated availability [7][8]. ### What is the latest research on BPC-157 and TB-500? Recent (2024-2026) literature includes a 2025 HSS Journal systematic review of BPC-157 (36 studies, only one human, "no clinical safety data") [6], a 2026 Sports Medicine review of approved and unapproved peptide therapies [7], a 2025 narrative review treating BPC-157 as investigational [8], and 2024-2025 BPC-157 musculoskeletal and cytoprotection studies in rats [9][10]. ## Efficacy questions ### Does the BPC-157 TB-500 blend help tendon and ligament injuries? In animal models, BPC-157 accelerated healing of a transected rat Achilles tendon [1] and was studied after surgical quadriceps detachment for muscle-to-bone reattachment [9]; Thymosin Beta-4 enhanced tissue healing in rats [4]. These are preclinical, single-compound findings — not evidence the combination helps human injuries. ### Does BPC-157 and TB-500 help muscle tears and recovery? Animal studies report BPC-157 effects on muscle-to-bone reattachment and tissue repair [9], and Thymosin Beta-4 acts as a myoblast chemoattractant in muscle injury [4]. Evidence is preclinical and single-compound; the combination's effect on human muscle recovery is unproven [6]. ### Does the BPC-157 TB-500 blend help wound healing? In animal models, Thymosin Beta-4 accelerated re-epithelialization, collagen deposition, and angiogenesis in wounds [4], and BPC-157 showed multi-tissue cytoprotection, including distant-organ protection after limb ischemia-reperfusion [10]. These are preclinical, single-compound findings, not human wound-healing evidence for the blend. ## Dosage and handling ### What is the half-life of BPC-157 and TB-500? BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog PK study. No specific half-life is established for the TB-500 heptapeptide (human PK data are for full-length thymosin beta-4), and none is validated for the blend [4]. ### How do you reconstitute a BPC-157 / TB-500 blend (10mg)? Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. This is research-handling context, not human-use guidance. ### How often should you inject BPC-157 and TB-500? There is no validated injection schedule for the blend. Community "loading then maintenance" protocols and fixed-ratio vials have no controlled-trial basis [6] and should not be presented as validated dosing. ### How do you cycle BPC-157 and TB-500? No controlled human trial defines a cycle for the blend. Community cycling and "loading then maintenance" schemes are not validated; reported animal doses are expressed per body weight in species-specific models [1][4] and do not translate to human cycling protocols. ## Safety and legality ### What are the side effects of BPC-157 and TB-500? Human safety data are scarce: a 2025 BPC-157 systematic review found "no clinical safety data" [6], and recent reviews note potential for serious harm from unapproved peptides used outside regulatory oversight [7]. A theoretical tumor/angiogenesis concern attaches to Thymosin Beta-4's pro-migratory, pro-angiogenic properties [4]. ### Does TB-500 cause cancer or promote tumor growth? Thymosin Beta-4 is implicated in tumor metastasis and angiogenesis, and the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression — a concern that compounds when two pro-repair peptides are combined [4]. This is a mechanistic concern, not a demonstrated human outcome. ### Are BPC-157 and TB-500 FDA approved or banned by WADA? Neither is approved by the FDA for human use [13], and both are prohibited by WADA (BPC-157 under the S0 non-approved-substances category; TB-500 / thymosin beta-4 under prohibited peptide and tissue-repair categories) [16]. The blend has no approved therapeutic indication. ### Is Wolverine legal? Neither constituent is an approved drug, and the blend has no approved therapeutic indication; both are in FDA's Category 2 for 503A compounding [13], are sold for laboratory use only, and are WADA-prohibited [16]. ### Can you get BPC-157 from a compounding pharmacy? Under current FDA status, BPC-157 is a Category 2 bulk drug substance (effective September 29, 2023) and is not eligible for routine 503A compounding while that status stands [13][15]. It is on the July 23-24, 2026 PCAC agenda as a candidate under evaluation [14] — a scheduled discussion, not a listing. ### What is the FDA 503A status of Wolverine? The blend is not an approved medicine; both constituents are in FDA's Category 2 for 503A compounding effective the September 29, 2023 list update [13], so neither is currently eligible for routine 503A compounding while that status stands [15]. Both are on the July 23-24, 2026 PCAC agenda as candidates under evaluation [14]. --- A street-wall research digest on the BPC-157 TB-500 Wolverine blend — each peptide tagged to its own studies, every blend-level gap sprayed in plain sight beside the FDA 503A line, with no clinic behind the wall and nothing here to dispense.